| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1044 | 2018 |
| Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis A Petzold, LJ Balcer, PA Calabresi, F Costello, TC Frohman, EM Frohman, ... The Lancet Neurology 16 (10), 797-812, 2017 | 544 | 2017 |
| Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 445 | 2016 |
| Clinical relevance of brain volume measures in multiple sclerosis N De Stefano, L Airas, N Grigoriadis, HP Mattle, J O’Riordan, ... CNS drugs 28, 147-156, 2014 | 386 | 2014 |
| Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study EH Martinez-Lapiscina, S Arnow, JA Wilson, S Saidha, JL Preiningerova, ... The Lancet Neurology 15 (6), 574-584, 2016 | 379 | 2016 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 354 | 2018 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 290 | 2017 |
| Geographical variations in sex ratio trends over time in multiple sclerosis M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ... PloS one 7 (10), e48078, 2012 | 278 | 2012 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 242 | 2017 |
| Predictors and dynamics of postpartum relapses in women with multiple sclerosis SE Hughes, T Spelman, OM Gray, C Boz, M Trojano, A Lugaresi, ... Multiple Sclerosis Journal 20 (6), 739-746, 2014 | 222 | 2014 |
| Defining reliable disability outcomes in multiple sclerosis T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ... Brain 138 (11), 3287-3298, 2015 | 218 | 2015 |
| Sex as a determinant of relapse incidence and progressive course of multiple sclerosis T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ... Brain 136 (12), 3609-3617, 2013 | 210 | 2013 |
| Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS KA Ribbons, P McElduff, C Boz, M Trojano, G Izquierdo, P Duquette, ... PloS one 10 (6), e0122686, 2015 | 207 | 2015 |
| Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ... Annals of Neurology 77 (3), 425-435, 2015 | 192 | 2015 |
| Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice JCC de Sa, L Airas, E Bartholome, N Grigoriadis, H Mattle, ... Therapeutic advances in neurological disorders 4 (3), 139-168, 2011 | 192 | 2011 |
| TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab C Oreja-Guevara, J Ramos-Cejudo, LS Aroeira, B Chamorro, ... BMC neurology 12, 1-6, 2012 | 162 | 2012 |
| Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus M Sepúlveda, T Armangué, N Sola-Valls, G Arrambide, JE Meca-Lallana, ... Neuroimmunology & Neuroinflammation 3 (3), e225, 2016 | 155 | 2016 |
| Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial Proc Natl Acad Sci U S A 23 (116(17)), 8463-8470, 2019 | 149* | 2019 |
| Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis J Rivera-Navarro, J Benito-León, C Oreja-Guevara, J Pardo, ... Multiple Sclerosis Journal 15 (11), 1347-1355, 2009 | 143 | 2009 |
| Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st century steering group P Rieckmann, D Centonze, I Elovaara, G Giovannoni, E Havrdová, ... Multiple sclerosis and related disorders 19, 153-160, 2018 | 137 | 2018 |
